Authera

Authera is a science-driven biotech founded in 2022, building on decades of foundational research in FcRn biology from its academic founders. The company operates a cutting-edge technology platform that integrates biochemical, cellular, and in vivo models to de-risk the development of novel biologics with fine-tuned FcRn interactions. With a lead program in pre-clinical development for severe eye diseases and recent non-dilutive grant funding, Authera is positioned to advance its pipeline while seeking strategic partnerships to explore the broad therapeutic utility of its platform.

A proprietary platform centered on the neonatal Fc receptor (FcRn) that enables the tailored design and selection of novel therapeutic antibodies and albumin-based molecules with fine-tuned binding and transport properties to achieve desired pharmacokinetic profiles.

In ophthalmology, AuT-1 competes with anti-VEGF therapies and newer long-acting agents. In the broader FcRn space, competitors include argenx, Immunovant, UCB, and Johnson & Johnson. Authera differentiates through its deep academic roots in FcRn biology and a platform focused on fine-tuning binding properties to create molecules with optimized pharmacokinetics for specific tissues like the eye.